3T磁共振场强下阿尔茨海默病的氘代谢成像:一项试点病例对照研究
这项前瞻性病例对照试点研究于2021年3月至2023年2月纳入10例临床诊断阿尔茨海默病患者和9例认知健康对照,在3T场强下口服氘标记葡萄糖后行氘代谢成像。全脑波谱显示阿尔茨海默病组2H-Glx与2H-葡萄糖峰信号比值低于对照组(0.41±0.09 vs 0.58±0.20,P=0.04),但磁共振波谱成像未显示区域信号差异。
要点
- 3T氘代谢成像可检测阿尔茨海默病患者全脑氧化葡萄糖代谢受损。
- 阿尔茨海默病组2H-Glx/2H-葡萄糖比值较对照组降低(P=0.04)。
- 磁共振波谱成像未能在预期代谢受损脑区定位这些改变。
核心结论
- 3T氘代谢成像显示阿尔茨海默病患者脑内氧化葡萄糖代谢受损,但未显示区域信号差异。
研究设计与样本
- 前瞻性病例对照试点研究,2021年3月至2023年2月招募,共19例参与者(10例阿尔茨海默病患者,9例认知健康对照),3T场强下使用定制鸟笼头线圈,口服氘标记葡萄糖0.75 g/kg后行全脑磁共振波谱和三维磁共振波谱成像(体素大小3.2 cm立方)。
诊断标准与关键数值
- 全脑波谱中阿尔茨海默病组2H-Glx与2H-葡萄糖峰信号比值为0.41±0.09,对照组为0.58±0.20,P=0.04;磁共振波谱成像未显示区域信号差异。
局限性
- 磁共振波谱成像未能在预期代谢受损区域定位这些改变,原文推测可能因空间分辨率不足。
- 原文为试点病例对照研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Impaired glucose metabolism is characteristic of several types of dementia, preceding cognitive symptoms and structural brain changes. Reduced glucose uptake in specific brain regions, detected using fluorine 18 (18F) fluorodeoxyglucose (FDG) PET, is a valuable diagnostic marker in Alzheimer disease (AD). However, the use of 18F-FDG PET in clinical practice may be limited by equipment availability and high cost. Purpose To test the feasibility of using MRI-based deuterium (2H) metabolic imaging (DMI) at a clinical magnetic field strength (3 T) to detect and localize changes in the concentration of glucose and its metabolites in the brains of patients with a clinical diagnosis of AD. Materials and Methods Participants were recruited for this prospective case-control pilot study between March 2021 and February 2023. DMI was performed at 3 T using a custom birdcage head coil following oral administration of deuterium-labeled glucose (0.75 g/kg). Unlocalized whole-brain MR spectroscopy (MRS) and three-dimensional MR spectroscopic imaging (MRSI) (voxel size, 3.2 cm cubic) were performed. Ratios of 2H-glucose, 2H-glutamate and 2H-glutamine (2H-Glx), and 2H-lactate spectroscopic peak signals to 2H-water peak signal were calculated for the whole-brain MR spectra and for individual MRSI voxels. Results A total of 19 participants, including 10 participants with AD (mean age, 68 years ± 5 [SD]; eight males) and nine cognitively healthy control participants (mean age, 70 years ± 6; six males) were evaluated. Whole-brain spectra demonstrated a reduced ratio of 2H-Glx to 2H-glucose peak signals in participants with AD compared with control participants (0.41 ± 0.09 vs 0.58 ± 0.20, respectively; P = .04), suggesting an impairment of oxidative glucose metabolism in AD. However, there was no evidence of localization of these changes to the expected regions of metabolic impairment at MRSI, presumably due to insufficient spatial resolution. Conclusion DMI at 3 T demonstrated impairment of oxidative glucose metabolism in the brains of patients with AD but no evidence of regional signal differences. © RSNA, 2024 Supplemental material is available for this article.
引用
- Khan AS, Peterson KA, Vittay OI, et al. Deuterium Metabolic Imaging of Alzheimer Disease at 3-T Magnetic Field Strength: A Pilot Case-Control Study. Radiology. 2024. PMID: 39012255. doi:10.1148/radiol.232407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。